Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter of 2021.
“We are very pleased with our first quarter 2021 financial results, as we have been commercializing DANYELZA® (naxitamab-gqgk) throughout the U.S. since the beginning of February and we are very pleased with our progress to date. In addition, we successfully completed a follow-on offering with gross proceeds of approximately $115 million and netted another $62 million from closing the sale of our Priority Review Voucher, after sharing the total sales price of $105 million with MSK pursuant to the terms of our license agreement. With a cash balance of $252 million, we believe we are well positioned to advance our pipeline in the coming years,” stated Thomas Gad, founder, Chairman and President.
Dr. Claus Moller, Chief Executive Officer, continued, “We successfully submitted the European Marketing Authorization Application for omburtamab to the European Medicines Agency (“EMA”) in April. In parallel, we are making good progress in the clinic and have continued to advance the earlier stage programs in our pipeline, including GPA33-SADA, where we reported radioactivity uptake with a tumor to blood ratio of 122 in a mouse model. We are planning for the first SADA IND later this year and target an IND for GPA33-SADA in 2022.”
Recent Corporate Developments
- Subsequent to the end of the first quarter, on April 27, 2021, Y-mAbs announced the submission to EMA of a European Marketing Authorization Application for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
- Also subsequent to the end of the first quarter, on April 20, 2021, Y-mAbs announced a regulatory update for resubmission of the BLA for omburtamab, reconfirming our aim to resubmit the BLA late in the second quarter or in the third quarter 2021.
- After the close of the first quarter, on April 12, 2021, Y-mAbs announced data from GPA33-SADA, which in a xenograft model of colorectal peritoneal carcinomatosis showed radioactivity uptake with a tumor to blood ratio of 122 measured 24 hours after injection. An IND for the GPA33-SADA is targeted for next year.
- On February 22, 2021, Y-mAbs announced the closing of a follow-on shelf public offering, including the full exercise of the underwriters’ overallotment option, resulting in gross proceeds to the Company of approximately $115.0 million.
Y-mAbs reported net income of $33.4 million, or $0.80 per basic share or $0.75 per diluted share, for the quarter ended March 31, 2021, compared to a net loss of $26.2 million, or ($0.66) per basic and diluted share, reported for the quarter ended March 31, 2020. The increased net income was caused by the DANYELZA revenues and the recording of the net proceeds from monetization of the DANYELZA Priority Review Voucher.
Y-mAbs reported net revenues of $5.4 million for the quarter ended March 31, 2021 from the sales of DANYELZA. No revenues were reported for the quarter ended March 31, 2020.
Research and Development
Research and development expenses were $21.6 million for the three months ended March 31, 2021, compared to $18.6 million for the three months ended March 31, 2020, an increase of $3.0 million. The increase in research and development expenses primarily reflects the following:
- $2.0 million increase in outsourced manufacturing;
- $2.5 million increase in personnel costs; and
- $0.8 million increase in clinical trials.
These increases were partially offset by a $3.1 million decrease in outsourced research and supplies.
Selling, General, and Administration
Selling, general, and administrative expenses were $12.0 million for the three months ended March 31, 2021, compared to $8.1 million for the three months ended March 31, 2020, an increase of $3.9 million. The increase in selling general and administrative expenses primarily reflects the following:
- $3.3 million increase in personnel costs.
Cash and Cash Equivalents
The Company had approximately $252.3 million in cash and cash equivalents as of March 31, 2021.
Webcast and Conference Call
The Company will host a conference call on Friday, May 7, 2021 at 9 a.m. Eastern Time. To participate in the call, please dial 877-407-0792 (domestic) or 201-689-8263 (international) and reference the access code 13718796. A webcast will be available at: http://public.viavid.com/index.php?id=144412
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans; current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Annual Report on Form 10-K and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
“DANYELZA” and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.
|Y-MABS THERAPEUTICS, INC.|
|Consolidated Balance Sheets|
|(in thousands, except share data)|
|March 31,||December 31,|
|Cash and cash equivalents||$||252,271||$||114,634|
|Accounts receivable, net||5,997||—|
|Other current assets||4,736||7,729|
|Total current assets||264,009||122,363|
|Property and equipment, net||2,095||1,825|
|Operating lease right-of-use assets||3,979||4,569|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Operating lease liabilities, current portion||1,971||1,966|
|Total current liabilities||17,000||19,535|
|Accrued milestone and royalty payments||2,250||2,695|
|Operating lease liabilities, long-term portion||1,515||2,013|
|Preferred stock, $0.0001 par value, 5,500,000 shares authorized at|
|March 31, 2021 and December 31, 2020; none issued at|
|March 31, 2021 and December 31, 2020||—||—|
|Common stock, $0.0001 par value, 100,000,000 shares authorized at|
|March 31, 2021 and December 31, 2020; 43,548,419 and 40,688,447|
|shares issued at March 31, 2021 and December 31, 2020, respectively||4||4|
|Additional paid in capital||504,091||391,558|
|Accumulated other comprehensive income / (loss)||(91||)||(526||)|
|TOTAL STOCKHOLDERS’ EQUITY||252,217||105,836|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||274,916||$||132,047|
|Y-MABS THERAPEUTICS, INC.|
|Consolidated Statements of Net Loss and Comprehensive Loss|
|(in thousands, except share and per share data)|
|Three months ended March 31,|
|Product revenue, net||$||5,383||$||—|
|OPERATING COSTS AND EXPENSES|
|Cost of goods sold||93||—|
|Research and development||21,579||18,622|
|Selling, general, and administrative||11,970||8,125|
|Total operating costs and expenses||33,642||26,747|
|Loss from operations||(28,259||)||(26,747||)|
|Gain from sale of priority review voucher||62,010||—|
|Interest and other income, net||(338||)||568|
|NET INCOME / (LOSS)||$||33,413||$||(26,179||)|
|Other comprehensive income|
|Foreign currency translation||435||25|
|COMPREHENSIVE INCOME / (LOSS)||$||33,848||$||(26,154||)|
|Net income/(loss) per share attributable to common stockholders, basic||$||0.80||$||(0.66||)|
|Weighted average common shares outstanding, basic||41,870,759||39,753,583|
|Net income/(loss) per share attributable to common stockholders, diluted||$||0.75||$||(0.66||)|
|Weighted average common shares outstanding, diluted||44,383,791||39,753,583|
Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
+1 646 885 8505